Eli Lilly Q3 Earnings: Record Revenues Push Up 2026 Guidance

Eli Lilly’s third-quarter financial performance significantly outperformed Wall Street expectations, driven by soaring demand for its blockbuster diabetes and obesity medications. The pharmaceutical giant has raised its full-year revenue outlook, signaling robust commercial momentum as the GLP-1 class continues to reshape the industry landscape and cement Lilly’s position as a market leader over its chief rival, Novo Nordisk.

Strong Q3 Beat Fuels Higher Full-Year Forecast

The company reported third-quarter earnings and revenue that blew past estimates, justifying a substantial upward revision in full-year projections. Lilly now expects 2026 revenue to come in between $91 billion and $92 billion, a significant jump from the previous guidance of $85 billion to $87 billion. Similarly, adjusted earnings per share are projected at $35 to $36, compared to the prior outlook of $35.50 to $36.50. While the underlying profit target was raised by $4.07 per share at the midpoint, one-time charges related to dealmaking partially offset this gain at $4.57 per share.

The GLP-1 Giants: Mounjaro and Zepbound Drive Performance

Resilient demand for Zepbound and Mounjaro has been the primary engine behind Lilly’s impressive quarterly results. Mounjaro’s worldwide revenue soared 65% to $10.72 billion, including roughly $5 billion from the U.S., surpassing analyst expectations of $10.10 billion. Internationally, sales outside the U.S. surged an impressive 93%. Meanwhile, Zepbound posted $5.35 billion in revenue, marking a 49% year-over-year increase, largely driven by domestic demand amid falling realized prices. These dual therapies underscore Lilly’s formidable market dominance.

New Entry Slips Slightly Against Wall Street Estimates

Despite the massive success of existing blockbusters, Lilly’s newly launched obesity pill, Foundayo—which received U.S. approval in April—missed analyst expectations with $184 million in sales for the quarter, falling short of the estimated $229 million. This marks the second earnings report to include revenue from the competing oral GLP-1 pill, highlighting the fierce competitive pressure in the weight loss treatment space and the challenge of entering the market at scale.

Offsetting Volume Gains With Lower Net Prices

Despite a 34% increase in U.S. revenue to $15.1 billion, Lilly saw a 7% decrease in realized prices for its GLP-1 medications. Outside the U.S., prices dropped 29%, yet global sales still jumped 47% to $9.3 billion due to a 76% surge in volume. Such mix shifts demonstrate the ongoing strategic efforts to expand coverage for obesity care, including Medicare’s temporary pilot program starting in July, which plays into Lilly’s ability to offset price cuts with expanded patient access.

Eli Lilly’s latest quarterly results reflect a period of immense commercial strength in the pharmaceutical sector. While the upwardly revised guidance points to sustained growth, the slight miss from Foundayo and the persistent pressure of lower net prices suggest that the company must continue navigating a complex pricing environment while aggressively pushing new therapies into a highly competitive market. The continued expansion of GLP-1 coverage and Lilly’s dealmaking spree will be closely watched as the company eyes further market dominance.

Business, Health, News, Pharmaceuticals, Diabetes, Weight Loss